TY - JOUR
T1 - Aggressive posterior retinopathy of prematurity in two cohorts of patients in South India
T2 - implications for primary, secondary, and tertiary prevention
AU - Shah, Parag K.
AU - Subramanian, Prema
AU - Venkatapathy, Narendran
AU - Chan, Robison Vernon Paul
AU - Chiang, Michael
AU - Campbell, John Peter
N1 - Funding Information:
This project was supported by grants R01EY19474, K12EY027720, and P30EY10572 from the National Institutes of Health (Bethesda, MD), and by unrestricted departmental funding and a Career Development Award (JPC) from Research to Prevent Blindness (New York, NY). None of the funding agencies had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.Disclosures: Michael F. Chiang is an unpaid member of the Scientific Advisory Board for Clarity Medical Systems (Pleasanton, CA), and a consultant for Novartis (Basel, Switzerland), and an initial member of Inteleretina (Honolulu, HI). R. V. Paul Chan is on the Scientific Advisory Board for Visunex Medical Systems (Pleasanton, CA), and a consultant for Genentech (South San Francisco, CA). Michael Chiang and J. Peter Campbell receive research support from Genentech.
Publisher Copyright:
© 2019 American Association for Pediatric Ophthalmology and Strabismus
PY - 2019/10
Y1 - 2019/10
N2 - Background: Aggressive posterior retinopathy of prematurity (APROP), which has a poor visual prognosis, is common in low- and middle-income countries (LMICs) as a result of suboptimal oxygen monitoring (primary prevention). The purpose of this study was to compare outcomes in APROP eyes treated with laser to eyes treated with antivascular endothelial growth factor (anti-VEGF) therapy. Methods: The medical records of a cohort of APROP eyes treated with anti-VEGF (2010-2018) and another of eyes treated with laser photocoagulation (2002-2010) at the same institution in South India were reviewed retrospectively and compared. The main outcome was the proportion of eyes developing retinal detachment during resolution of acute ROP. Results: A total of 398 eyes of 199 preterm babies with APROP were included: 168 eyes were treated with photocoagulation; 230, with anti-VEGF. From 2002 to 2010, compared to the more recent cohort, babies diagnosed with APROP tended to be heavier (P < 0.001), older (P < 0.001), and exposed to fewer days of oxygen (P = 0.02). In the laser-treated cohort, 17 of 168 eyes (10%) developed retinal detachment (7, stage 5; 12, stage 4), compared with 3 of 230 (1%) in the anti-VEGF cohort (all stage 4 [P = 0.002]). Conclusions: The incidence of retinal detachment was significantly lower in eyes treated with anti-VEGF compared with laser-.treated eyes In the absence of a randomized trial, these data suggest that anti-VEGF may lead to better anatomic outcomes, although questions remain concerning dosage, timing, and risks.
AB - Background: Aggressive posterior retinopathy of prematurity (APROP), which has a poor visual prognosis, is common in low- and middle-income countries (LMICs) as a result of suboptimal oxygen monitoring (primary prevention). The purpose of this study was to compare outcomes in APROP eyes treated with laser to eyes treated with antivascular endothelial growth factor (anti-VEGF) therapy. Methods: The medical records of a cohort of APROP eyes treated with anti-VEGF (2010-2018) and another of eyes treated with laser photocoagulation (2002-2010) at the same institution in South India were reviewed retrospectively and compared. The main outcome was the proportion of eyes developing retinal detachment during resolution of acute ROP. Results: A total of 398 eyes of 199 preterm babies with APROP were included: 168 eyes were treated with photocoagulation; 230, with anti-VEGF. From 2002 to 2010, compared to the more recent cohort, babies diagnosed with APROP tended to be heavier (P < 0.001), older (P < 0.001), and exposed to fewer days of oxygen (P = 0.02). In the laser-treated cohort, 17 of 168 eyes (10%) developed retinal detachment (7, stage 5; 12, stage 4), compared with 3 of 230 (1%) in the anti-VEGF cohort (all stage 4 [P = 0.002]). Conclusions: The incidence of retinal detachment was significantly lower in eyes treated with anti-VEGF compared with laser-.treated eyes In the absence of a randomized trial, these data suggest that anti-VEGF may lead to better anatomic outcomes, although questions remain concerning dosage, timing, and risks.
UR - http://www.scopus.com/inward/record.url?scp=85072626627&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072626627&partnerID=8YFLogxK
U2 - 10.1016/j.jaapos.2019.05.014
DO - 10.1016/j.jaapos.2019.05.014
M3 - Article
C2 - 31521847
AN - SCOPUS:85072626627
SN - 1091-8531
VL - 23
SP - 264.e1-264.e4
JO - Journal of AAPOS
JF - Journal of AAPOS
IS - 5
ER -